Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

(2011) Marcus M. Schittenhelm et al.   CELL CYCLE

Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3

(2009) S. Fukuda et al.   BLOOD

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

(2009) J. Zhou et al.   BLOOD

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells

(2008) E. Weisberg et al.   BLOOD

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML

(2008) L. Bullinger et al.   BLOOD

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

(2008) E. Weisberg et al.   BLOOD

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD

Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication

(2008) Adam J. Mead et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas

(2008) Emily Chan et al.   INVESTIGATIONAL NEW DRUGS

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment

(2008) U Mony et al.   LEUKEMIA

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells

(2008) Chie Nishioka et al.   LEUKEMIA RESEARCH

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE